DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
The DOI matches its Crossref record; 119 of the 121 references it cites were found in a registry or an index.
Abstract
Etonitazene and related 2-benzylbenzimidazoles are potent analgetics invented in the research laboratories of the Swiss pharmaceutical giant CIBA in the late 1950s. Though the unprecedented structure distinguishes this class of compounds from poppy-derived and other synthetic analgetics, a range of studies indicate that these drugs are selective μ opioid receptor agonists possessing morphine-like pharmacotoxicological properties in animals as well as humans. Several unscheduled members of this synthetically readily accessible class of opioids that are not controlled under the international and national drug control systems have recently emerged on the illicit drug market. Among them, isotonitazene has been implicated in at least 200 fatalities in Europe and North America. None of the 2-benzylbenzimidazole derivatives have been developed into medicines, but etonitazene and some of its derivatives have been used as receptor probes and in addiction behavior studies in animals. The unique structure has inspired research on such benzimidazoles and related benzimidazolones of which "brorphine" made its debut as one of the newest psychoactive substance to emerge on the illicit opioid drug market in mid-2019. This in-depth review provides a historical introduction, an overview on the chemistry, pharmacological profiles, adverse effects, addiction liability, regulatory status, and the impact on chemical neuroscience of the 2-benzylbenzimidazoles. Structurally related benzimidazoles with opioid and/or analgesic properties are also discussed briefly.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The drug class was developed and investigated by the pharmaceutical industry in the 1950s and 1960s but never reached clinical use because the balance between their therapeutic and toxic effects was less favourable than that of morphine [3]”
From Nitazenes: review of comparative pharmacology and antagonist action (2025) · cites this paper as [3]
In the citing paper
“While the NSO market is currently largely dominated by benzimidazole opioids (Ujváry et al., 2021)”
From Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization (2024) · cites this paper as Ujváry et al., 2021
In the citing paper
“Notably, brorphine appeared on recreational drug markets around the globe from 2019 onwards (Krotulski et al., 2020b; Ujváry et al., 2021; Vandeputte et al., 2022a; Verougstraete et al., 2020) and was also identified in (postmortem) toxicology samples (Krotulski et al., 2020a; Verougstraete et al., 2020; Vohra et al., 2021).”
From Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization (2024) · cites this paper as Ujváry et al., 2021
Citations
Cites
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567
Stein, C. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062613-093100 · Cited by 480
Ghose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Properties of Opiate-Receptor Binding in Rat Brain
Pert, C. B., & Snyder, S. H. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.8.2243 · Cited by 438
Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex
Krishna Kumar, K., Shalev-Benami, M., Robertson, M. J., Hu, H., Banister, S. D., Hollingsworth, S. A., Latorraca, N. R., Kato, H. E., Hilger, D., Maeda, S., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.040 · Cited by 419
HUGHES, J., KOSTERLITZ, H. W., & LESLIE, F. M. (1975) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1975.tb07373.x · Cited by 403
Gaba, M., & Mohan, C. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1495-5 · Cited by 366
A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS
TYERS, M. B. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb07041.x · Cited by 341
Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human
Morgan, M. M., & Christie, M. J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01335.x · Cited by 270
Imidazole and Benzimidazole Synthesis
(1997) · Elsevier eBooks · doi:10.1016/b978-0-12-303190-7.x5012-2 · Cited by 237
Research works printed but not linked: 36
- Gulland J. M., 1925, Mem. Proc. Manchester Lit. Philos. Soc., 69, 79
- European Monitoring Centre for Drugs and Drug Addiction, 2020, European Drug Report 2020: Trends and Developments
- United Nations Office on Drugs and Crime, 2021, World Drug Report 2020
- United Nations Office on Drugs and Crime. growing complexity of the opioid crisis. Global SMART Update Vol. 24, UNODC, Vienna, 2020. https://www.unodc.org/documents/scientific/Global_SMART-2020-Vol_24_web.pdf (accessed Feb 24, 2021).
- Grimmett M. R., 2002, Hetarenes and Related Ring Systems. Five-Membered Hetarenes with Two Nitrogen or Phosphorus Atoms, Science of Synthesis, 12, 529
- StarDrop , version 6.6 software, Optibrium Ltd., Cambridge, U.K.
- Sparatore F., 1968, Farmaco, Ed. Sci., 23, 344
- Bucha M., 2018, Indian J. Heterocycl. Chem., 28, 321
- European Monitoring Centre for Drugs and Drug Addiction, 2020, Risk assessment report on the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No. 1920/2006 (as amended)
- Gonthier, V. Une toute nouvelle drogue inquiete les autorites. Le Journal du Quebec. 1 Février, 2020. https://journaldequebec.com/2020/02/01/une-toute-nouvelle-drogue-inquiete-les-autorites (accessed Feb 24, 2021).
- Sorokin V. I., 1999, J. Clandestine Lab. Invest. Chem. Assoc., 9, 20
- Brittain R. T., 1973, Br. J. Pharmacol., 49, 158P
- Jacobson A. E., 1992, Problems of Drug Dependence, 1991, NIDA Research Monograph Series 119, 490
- Aceto M. D., 1994, Problems of Drug Dependence, 1993, NIDA Research Monograph Series 140, 103
- Aceto M. D., 1992, Problems of Drug Dependence, 1991, NIDA Research Monograph Series 119, 513
- Eddy N. B., 1959, Chem. Ind., 47, 1462
- Fraser H. F., 1960, Minutes of the Twenty-First Meeting, 11–12 January, 1960, Committee on Drug Addiction and Narcotics, 35
- 1961, World Health Organization Technical Report Series No. 211, 1
- Butelman E. R., 1993, J. Pharmacol. Exp. Ther., 264, 145
- Emmerson P. J., 1994, J. Pharmacol. Exp. Ther., 271, 1630
- Toll L., 1998, NIDA Research Monograph Series 178, 440
- Rothman R. B., 1985, Mol. Pharmacol., 27, 399
- Lecolier S., 1967, Chim. Ther., 2, 16
- Lénárd K., 1962, Acta Chim. Acad. Sci. Hung., 34, 439
- Janssen P. A. J., 1971, Arzneim.-Forsch., 21, 862
- Li Q., 1984, Acta Pharm. Sin., 19, 124
- Department of Justice., 2021, Fed. Regist., 86, 11862
- Holliday E. R., 1949, J. Pharm. Pharmacol., 1, 734
- Ramsh S. M., 2011, Stud. Hist. Biol., 3, 36
- Feitelson B. N., 1958, J. Chem. Soc., 2426
- Brandenberger H., 1974, Dtsch. Lebensmitt. Rundsch., 70, 31
- Anonymous., 1987, BKA - Wöchentlicher Lagebericht, 87, 9
- Sorokin V. I., 1999, Microgram, 32, 239
- Anonymous., 2003, Microgram Bull., 36, 275
- deStevens G., 1965, Analgetics, 405
- Archer S., 1965, Progr. Drug Res., 8, 261
Cited by
Items 101–141 of 141
Synthetic Opioids as New Psychoactive Substances (NPS)
Cruz, S. L., & Martín-del-Campo, R. (2022) · Springer eBooks · doi:10.1007/978-3-031-09936-6_16 · Cited by 3
Sisco, E., Burns, A., & Moorthy, A. S. (2021) · doi:10.33774/chemrxiv-2021-0pcnq · Cited by 2
The Nitazene Era: A Critical Turning Point in the Synthetic Opioid Crisis Beyond Fentanyl
Dow, L. F., Abisogun, A. A., Berida, T. I., Krishnan, S. C., Rathnayake, U., & Lindsley, C. W. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00696 · Cited by 3
Trivedi, R. R., Luo, D., Hessing, M. C., Prantzalos, E. R., Alilain, W. J., Turner, J. R., & Prisinzano, T. E. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117991 · Cited by 1
McNicholas, R., Sweeney, N., Fenton, F., & Keenan, E. (2025) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2025.10102 · Cited by 1
Nitazenes: Are pain physicians aware of the risks?
Mortman, R. J., Durbhakula, S., & Emerick, T. D. (2025) · Pain Medicine · doi:10.1093/pm/pnaf127 · Cited by 1
Kashindye, R. C., Yadav, D., & Yadav, R. (2026) · Journal of Forensic and Legal Medicine · doi:10.1016/j.jflm.2026.103069 · Cited by 2
Availability of nitazenes via cryptomarkets and surface web shops: An observational study
Man, N. W. Y., Barratt, M. J., Sutherland, R., Bruno, R., Graham, C., Sadaphale, V., & Peacock, A. (2026) · Addiction · doi:10.1111/add.70350 · Cited by 2
Xu, F., Zhang, S.-Y., Huo, J.-Q., Zeng, F., Zhou, F.-K., & Barboni, L. (2026) · Organic & Biomolecular Chemistry · doi:10.1039/d6ob00074f · Cited by 1
Super-potent opioids could be safer-than-expected alternatives to conventional painkillers
Mathis, V., & Darcq, E. (2026) · Nature · doi:10.1038/d41586-026-00806-3 · Cited by 1
Identification of isotocyanozene at an Australian drug checking service
Curtis, B., Lawes, D. J., Persson, M., Caldicott, D. G. E., Gréen, H., Norman, C., & McLeod, M. D. (2026) · Forensic Chemistry · doi:10.1016/j.forc.2026.100744 · Cited by 2
Jahan, K., Glatfelter, G. C., Sanchez, J., Maitland, A. D., Bonifazi, A., Saab, E., Keegan, B. M., Rais, R., Bi, G., Gomez, J. L., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119079 · Cited by 1
Price of Nitazenes for Sale on Cryptomarkets and Surface Web Shops
Man, N. W. Y., Barratt, M. J., Bruno, R., Graham, C., Sadaphale, V., Peacock, A., & Sutherland, R. (2026) · Drug and Alcohol Review · doi:10.1111/dar.70202 · Cited by 1
Danyliuk, I. Y., Tolmachova, V. S., Shishkina, S. V., & Вовк, М. В. (2023) · ChemistrySelect · doi:10.1002/slct.202300084 · Cited by 1
Tsai, M.-H. M., Chen, L., Baumann, M. H., Canals, M., Javitch, J. A., Lane, J. R., & Shi, L. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.10.566672 · Cited by 1
A Putative Binding Model of Nitazene Derivatives at the μ -Opioid ReceptorPreprint
Clayton, J., Shi, L., Robertson, M. J., Skiniotis, G., Michaelides, M., Stavitskaya, L., & Shen, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.03.616560 · Cited by 1
Substances Not Listed in the International Conventions
(2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166631-00173
NPS chemistry, classification, and metabolism
Gerona, R. R. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-811764-4.00001-x
Gerona, R. R. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-811764-4.00005-7
Paavola, J., Skolnick, P., Wheeler, A., Mankabady, B., Laffont, C. M., & Heidbreder, C. A. (2025) · Cureus · doi:10.7759/cureus.95174
Palathinkal, A. B., Basha, S. F., Laya, S., Nalakath, J., Komathu, P. O., Naduvilakkandy, R., Joseph, M., & Jose, S. V. (2025) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.70005 · Cited by 1
Miller, C. O. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-13315-1_3
Barra, B. F. C., Pereira, J. R. P., Ferreira, D. R., Oeri, H. E., Martins, D. J. M., Almeida, R. M., Oatley, G., Neng, N. R., Gaspar, H., & Quintas, A. (2026) · Scientific Reports · doi:10.1038/s41598-026-35256-4 · Cited by 1
Membrane Permeability Drives the Extreme Potency of Fentanyl
Clayton, J., Farmer, G. J., Glenn, J., Mistry, S. N., Lane, J. R., Shi, L., Stavitskaya, L., Canals, M., & Shen, J. K. (2026) · JACS Au · doi:10.1021/jacsau.5c01666
Coordinated subpocket engagement underlies nitazene potency at the µ-opioid receptorPreprint
Robinson, M. J., Chen, L., Thakur, A., Lee, K.-H., & Shi, L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.27.721072
Mechanistic insights into nitazenes at the μ-opioid receptor
Xia, L., Jin, M., & Lu, L. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.04.009
Commentary on Zhu et al .: Nitazenes—Tracking a moving target from linked United States databases
Stove, C. P., & Vandeputte, M. M. (2026) · Addiction · doi:10.1111/add.70480
Untargeted LC-HRMS impurity profiling for forensic chemical intelligence
Caprari, C., Ferri, E., Rossetti, P., Gregori, A., Citti, C., & Cannazza, G. (2026) · Forensic Chemistry · doi:10.1016/j.forc.2026.100755
Zemp, S., Alluisetti, G., Weinmann, W., Schrag, B., Sporkert, F., Leclerc, M., & Grafinger, K. E. (2026) · Drug Testing and Analysis · doi:10.1002/dta.70095
Rombolà, F., Maurizzi, D., Silla, A., Caliceti, C., Bilel, S., Hrelia, P., Malaguti, M., Lenzi, M., & Marti, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125360
Preclinical pharmacology of N-pyrrolidino “nitazene” opioids appearing in nonmedical drug markets
Glatfelter, G. C., Maitland, A. D., Gonzalez, N. R., Walther, D. M., Chen, L., Shi, L., & Baumann, M. H. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104977
Coordinated Subpocket Engagement Underlies Nitazene Potency at the μ-Opioid Receptor
Robinson, M. J., Chen, L., Thakur, A., Lee, K.-H., & Shi, L. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00311
Upadhyay, N., Neel, L. T., Li, E., Silte, A. A., Lyu, R., Selley, D. E., Dewey, W. L., Zhang, Y., & Pagare, P. P. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00283
Niżnik, Ł., & Jurowski, K. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.112263
Miskulin, A., Shkolnikov, I., Sboto, J. N. S., Kielty, C., Wallace, B. B., Gill, C. G., & Hore, D. K. (2026) · Drug Testing and Analysis · doi:10.1002/dta.70135
In Vitro Pharmacological Characterization of a Series of 5‐Cyano Desnitazene Opioids or “Cyanazenes”
Lambrecht, I. M., Stove, C. P., & Vandeputte, M. M. (2026) · Drug Testing and Analysis · doi:10.1002/dta.70133
Acute toxic leucoencephalopathy following protonitazene ingestion
O’Laoi, R., Acton, H., Kavanagh, P., Hunt, I., Sheehy, N. P., & Kennedy, C. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70817
Kutzler, J., Postupka, A., & Auwärter, V. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04546-1 · Cited by 1
Forgiftningsutbrudd med nye potente rusmidler – er Norge forberedt?
Vevelstad, M. S., Edland-Gryt, M., Freng, E., Finstad, S., Frost, J., von Krogh, A., Skulberg, A. K., Drange, E., & Bjørnaas, M. A. (2026) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.26.0430
Zhu, S., Yu, D., Shi, X., Liu, Y., Zong, Y., Wu, N., Wang, N., Tong, G., Liu, Y., Zhang, H., et al. (2026) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2026.117762
Characterization of pharmacological inhibition of the hERG potassium channel by nitazene opioidsPreprint
Chowdhury, M. R., Baque, M., Osborne, T., Cheng, H., Hannington, O., Zhang, Y., Harchi, A. E., Copeland, C. S., Corey, R. A., Harmer, S. C., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-11234286/v1
Metadata
- Authors
- Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R.
- Affiliations
- iKem BT, H-1033 Budapest, Hungary
- European Monitoring Centre for Drugs and Drug Addiction (PT)
- European Monitoring Centre for Drugs and Drug Addiction, 1249-289 Lisbon, Portugal
- Corresponding author
- Ujváry, István
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-03-24
- Volume
- 12
- Issue
- 7
- Pages
- 1072-1092
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W3137216449
- Cited by
- 141
- References
- 121
- Citations by year
- 2026: 34 · 2025: 31 · 2024: 27 · 2023: 20 · 2022: 21 · 2021: 8
- FWCI
- 12.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Monitoring Centre for Drugs and Drug Addiction (CT.20.SAS.0017.1.0)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- etonitazene, isotonitazene, mu-opioid receptor agonists, synthetic opioids, benzimidazolone, analgesics, drug regulation, addiction liability, pharmacotoxicology, Ciba, drug development history
- MeSH terms
- Analgesics, Opioid, Animals, Benzimidazoles, Europe, Humans, Morphine, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.